Scarica l'app Stockscreener
2.45
0.82%
0.02
Dopo l'orario di chiusura:
2.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.43
Aprire:
$2.44
Volume 24 ore:
1.01M
Relative Volume:
0.57
Capitalizzazione di mercato:
$162.99M
Reddito:
$488.00K
Utile/perdita netta:
$-41.44M
Rapporto P/E:
-2.6344
EPS:
-0.93
Flusso di cassa netto:
$-31.47M
1 W Prestazione:
+0.41%
1M Prestazione:
-39.80%
6M Prestazione:
-40.96%
1 anno Prestazione:
+8.89%
Intervallo 1D:
$2.4201
$2.50
Intervallo di 1 settimana:
$2.2908
$2.50
Portata 52W:
$2.09
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Nome
Cardiff Oncology Inc
Settore
Industria
Telefono
858-952-7570
Indirizzo
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Confronta CRDF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.45 | 161.66M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2025-06-24 | Iniziato | Jefferies | Hold |
| 2024-09-06 | Iniziato | Craig Hallum | Buy |
| 2022-01-05 | Iniziato | William Blair | Outperform |
| 2021-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-09 | Ripresa | Maxim Group | Buy |
| 2020-10-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
Cardiff Oncology Price Target Cut to $10 by H.C. Wainwright. - AInvest
H.C. Wainwright lowers Cardiff Oncology stock price target on trial data - Investing.com Nigeria
Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom - insights.citeline.com
How does Cardiff Oncology Inc. generate profit in a changing economyAchieve breakthrough gains with smart trades - Jammu Links News
What is the dividend policy of Cardiff Oncology Inc. stockGet real-time alerts on top stocks - Jammu Links News
Why is Cardiff Oncology Inc. stock attracting strong analyst attentionFree Popular Stock Recommendations - Jammu Links News
Should I hold or sell Cardiff Oncology Inc. stock in 2025Maximize returns with disciplined investment techniques - Jammu Links News
What institutional investors are buying Cardiff Oncology Inc. stockUnstoppable profit momentum - Jammu Links News
Is Cardiff Oncology Inc. stock overvalued or undervaluedMarket-crushing stock picks - Jammu Links News
How strong is Cardiff Oncology Inc. company’s balance sheetFree Risk Assessment Services - Jammu Links News
What analysts say about Cardiff Oncology Inc. stockGrow your wealth with proven stock picks - Jammu Links News
What drives Cardiff Oncology Inc. stock priceUnrivaled growth potential - Jammu Links News
What is the risk reward ratio of investing in Cardiff Oncology Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What catalysts could drive Cardiff Oncology Inc. stock higher in 2025Free Investment Risk Control - Jammu Links News
Is Cardiff Oncology Inc. a good long term investmentHigh-return market picks - Jammu Links News
When is Cardiff Oncology Inc. stock expected to show significant growthSuperior returns - Jammu Links News
Is Cardiff Oncology Inc. a growth stock or a value stockNavigate the market with precision tools - Jammu Links News
Both Individual Investors Who Control a Good Portion of Cardiff Oncology, Inc. (NASDAQ:CRDF) Along With Institutions Must Be Dismayed After Last Week's 42% Decrease - 富途牛牛
Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - inkl
Cardiff Oncology Insiders Land Bargain With Gains Of US$244k - Yahoo Finance
Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
Cardiff Oncology (CRDF.O) Plummets 27%: What's Behind the Sharp Intraday Move? - AInvest
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2 - Benzinga
Cardiff Oncology Plunges 26.59% on Earnings Miss - AInvest
Cardiff Oncology 2025 Q2 Earnings Financial Struggles as Net Income Declines 18.4% - AInvest
Cardiff Oncology Reports Q2 2025 Financial Results - TipRanks
Cardiff Oncology shares fall 26.89% after-hours after reporting a wider Q2 net loss. - AInvest
Cardiff Oncology shares plunge after Q2 earnings miss By Investing.com - Investing.com South Africa
Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004) - TradingView
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cardiff Oncology: Q2 Earnings Snapshot - San Francisco Chronicle
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com
Cardiff Oncology reports results from colorectal cancer trial - Seeking Alpha
Cardiff Oncology reports positive data from colorectal cancer trial By Investing.com - Investing.com Nigeria
Cardiff Oncology reports positive data from colorectal cancer trial - Investing.com Australia
Cardiff Oncology Announces Positive Data from Ongoing Randomized - GuruFocus
Cardiff Oncology Announces Positive Data from Ongoing - GlobeNewswire
Breakthrough: New Cancer Drug Achieves 49% Response Rate vs 30% Standard Care in Colorectal Cancer Trial - Stock Titan
Clinical Trial Success: Cardiff Oncology Advances Colorectal Cancer Treatment with 40% Response Rate - Stock Titan
How Cardiff Oncology Inc. stock performs during market volatilityOversold Stock Bounce Playbook Generator - Newser
Is Cardiff Oncology Inc. stock a growth or value playFree Growth Based Stock Signal Screener - Newser
Is Cardiff Oncology Inc. Stock Overbought or Oversold RSI Indicator AnalysisReal Trader Watchlist with Entry Targets - Newser
Pancreatic Ductal Adenocarcinoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix - Barchart.com
How volatile is Cardiff Oncology Inc. stock compared to the marketGet alerts on the hottest market movers - Jammu Links News
Cardiff Oncology Inc Azioni (CRDF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):